Jun 15, 2022 / 09:00PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Good afternoon. We'll continue with the next session. I'm Paul Choi, and I cover the SMid Cap Biotechnology sector here at the firm. And it's my pleasure to welcome BridgeBio for this session. From management joining us is Founder and CEO, Neil Kumar. What we'll do is Q&A. If any audience members along the way have any questions for Neil, please feel free to raise your hand, and we'll try and get a mic to you. But maybe before we start with Q&A, Neil, maybe if you want to provide some any high-level comments that you think are of interest. Otherwise, we can just go into Q&A.
Neil Kumar - BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director
Yes, sure. Happy to. First of all, thanks, everyone, for the time. I think our strategy a bit large over the next 18 months or so is informed by 2 inputs, really, number 1 is our continued belief in our late-stage pipeline of Phase II or Phase III assets in $1 billion-plus markets. And we can talk about those, but those are five
BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers